Asymmetric dimethylarginine (ADMA) in children with diabetes type 1;Asymetryczna dimetyloarginina (ADMA) u dzieci z cukrzyca̧ typu 1

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 16, Issue 3, 2010, Pages 137-141

  Głowińska Olszewska, Barbara ^a   Łuczyński, Włodzimierz ^a   Jabłońska, Jolanta ^a   Otocka, Agnieszka ^a   Florys, Bozena ^a   Bossowski, Artur ^a  

^a Klinika Pediatrii   (Poland)

Author keywords

ADMA; Children; Diabetes type 1

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

EID: 84904849633     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rossing P., Hougaard P., Borch-Johnsen K. i wsp.: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br. Med. J., 1996, 313, 779-784.
2. Cooke J.P., Dzau V.J.: Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med., 1997, 48, 489-509.
3. Achan V., Broadhead M., Malaki M. i wsp.: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1455-1459.
4. Leiper J., Vallance P.: Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res., 1999, 43, 542-548.
5. MacAllister R.J., Parry H., Kimoto M. i wsp.: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol., 1996, 119, 1533-1540.
6. Vallance P., Leone A., Calver A. i wsp.: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992, 339, 572-575.
7. Krzyzanowska K., Mittermayer F., Wolzt M. i wsp.: ADMA, cardiovascular disease and diabetes. Diabetes Res. Clin. Pract., 2008, 82 (supl. 2), S122-126.
8. Antoniades C., Shirodaria C., Leeson P. i wsp.: Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur. Heart J., 2009, 30, 1142-1150.
9. Boger R.H.: The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res., 2003, 59, 824-833.
10. De Gennaro Colonna V., Bianchi M. i wsp.: Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med. Sci. Monit., 2009, 15, RA91-RA101.
11. Furuki K., Adachi H., Matsuoka H. i wsp.: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis, 2007, 191, 206-210.
12. Altinova A.E., Arslan M., Sepici-Dincel A. i wsp.: Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J. Clin. Endocrinol. Metab., 2007, 92, 1881-1885.
13. Cighetti G., Fermo I., Aman C.S. i wsp.: Dimethylarginines in complicated type 1 diabetes: roles of insulin, glucose, and oxidative stress. Free Radic. Biol. Med., 2009, 47, 307-311.
14. Heilman K., Zilmer M., Zilmer K. i wsp.: Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes. Scand. J. Clin. Lab. Invest., 2009, 69, 85-91.
15. Jehlicka P., Stozicky F., Mayer O.Jr. i wsp.: Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol. Res., 2009, 58, 179-184.
16. Pitocco D., Zaccardi F., Di Stasio E. i wsp.: Role of asymmetric-dimethyl-L-arginine (ADMA) and nitrite/nitrate (NOx) in the pathogenesis of oxidative stress in female subjects with uncomplicated type 1 diabetes mellitus. Diabetes Res. Clin. Pract., 2009, 86, 173-176.
17. Tarnow L., Hovind P., Teerlink T. i wsp.: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care, 2004, 27, 765-769.
18. Lajer M., Tarnow L., Jorsal A. i wsp.: Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2008, 31, 747-752.
19. Lin K.Y., Ito A., Asagami T. i wsp.: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-992.
20. Paiva H., Lehtimaki T., Laakso J. i wsp.: Plasma concentrations of asymmetric-dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism, 2003, 52, 303-307.
21. Krzyzanowska K., Mittermayer F., Krugluger W. i wsp.: Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis, 2006, 189, 236-240.
22. Krzyzanowska K., Mittermayer F., Wolzt M. i wsp.: Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care, 2007, 30, 1834-1839.
23. Yazici D., Yavuz D.G., Unsalan S. i wsp.: Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients. J. Endocrinol. Invest., 2007, 30, 726-733.
24. Perticone F., Sciacqua A., Maio R. i wp.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 2009, 142, 236-241.
25. Curgunlu A., Uzun H., Bavunoglu I. i wsp.: Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J. Hum. Hypertens., 2005, 19, 629-633.
26. Perticone F., Sciacqua A., Maio R. i wsp.: Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol., 2005, 46, 518-523.
27. Osanai T., Saitoh M., Sasaki S. i wsp.: Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension, 2003, 42, 985-990.
28. Mittermayer F., Pleiner J., Krzyzanowska K. i wsp.: Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien. Klin. Wochenschr., 2005, 117, 816-820.
29. Głowińska-Olszewska B., Urban M., Łuczyński W. i wsp.: Korelacja miȩdzy asymetryczna̧ dimetyloarginina̧, homocysteina̧ oraz insulinoopornościa̧ u młodzież y z zespołem metabolicznym. Endokrynol. Otyłość Zaburz. Przem. Materii, 2009, 5, 185-191.
30. Gruber H.J., Mayer C., Meinitzer A. i wsp.: Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp. Clin. Endocrinol. Diabetes, 2008, 116, 520-524.
31. Ayer J.G., Harmer J.A., Nakhla S. i wsp.: HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 943-949.